Thermador Groupe SA (EPA:THEP)
France · Delayed Price · Currency is EUR 80.20
-0.20 (-0.25%)
Aug 13, 2025, 5:35 PM CET
Ligand Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 491.03 | 503.89 | 580.95 | 553.86 | 486.5 | 395.5 | Upgrade | |
Revenue Growth (YoY) | -7.15% | -13.26% | 4.89% | 13.85% | 23.01% | 7.23% | Upgrade |
Cost of Revenue | 311.4 | 321.4 | 374.44 | 361.01 | 311.24 | 252.15 | Upgrade |
Gross Profit | 179.63 | 182.49 | 206.51 | 192.85 | 175.26 | 143.35 | Upgrade |
Selling, General & Admin | 106.63 | 105.7 | 109.17 | 100.63 | 90.88 | 80.38 | Upgrade |
Other Operating Expenses | 5.51 | 5.43 | 5.96 | 4.46 | 4.08 | 5.06 | Upgrade |
Operating Expenses | 123.63 | 122.32 | 125.67 | 113.25 | 102.06 | 91.94 | Upgrade |
Operating Income | 56 | 60.17 | 80.84 | 79.59 | 73.2 | 51.41 | Upgrade |
Interest Expense | -1.2 | -1.1 | -1.32 | -0.58 | -0.22 | -0.25 | Upgrade |
Interest & Investment Income | 1.54 | 1.47 | 0.22 | 0.04 | 0 | - | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | - | - | -0.14 | Upgrade |
EBT Excluding Unusual Items | 56.34 | 60.54 | 79.73 | 79.05 | 72.98 | 51.02 | Upgrade |
Pretax Income | 56.34 | 60.54 | 79.73 | 79.05 | 72.98 | 51.02 | Upgrade |
Income Tax Expense | 14.67 | 15.8 | 21.43 | 20.15 | 20.08 | 14.84 | Upgrade |
Earnings From Continuing Operations | 41.67 | 44.74 | 58.3 | 58.9 | 52.9 | 36.18 | Upgrade |
Minority Interest in Earnings | - | - | - | - | -0 | -0 | Upgrade |
Net Income | 41.67 | 44.74 | 58.3 | 58.9 | 52.9 | 36.18 | Upgrade |
Net Income to Common | 41.67 | 44.74 | 58.3 | 58.9 | 52.9 | 36.18 | Upgrade |
Net Income Growth | -15.14% | -23.25% | -1.02% | 11.34% | 46.21% | 11.76% | Upgrade |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | 9 | Upgrade |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade |
Shares Change (YoY) | -0.48% | -0.31% | 0.03% | - | -0.02% | 0.95% | Upgrade |
EPS (Basic) | 4.55 | 4.88 | 6.34 | 6.40 | 5.75 | 3.93 | Upgrade |
EPS (Diluted) | 4.32 | 4.63 | 6.01 | 6.07 | 5.45 | 3.73 | Upgrade |
EPS Growth | -14.66% | -22.96% | -0.99% | 11.38% | 46.11% | 10.68% | Upgrade |
Free Cash Flow | 48.78 | 70.2 | 48.86 | 14.14 | 16.28 | 28.63 | Upgrade |
Free Cash Flow Per Share | 5.05 | 7.26 | 5.04 | 1.46 | 1.68 | 2.95 | Upgrade |
Dividend Per Share | 2.080 | 2.080 | 2.080 | 2.080 | 2.000 | 1.820 | Upgrade |
Dividend Growth | - | - | - | 4.00% | 9.89% | 1.11% | Upgrade |
Gross Margin | 36.58% | 36.22% | 35.55% | 34.82% | 36.02% | 36.24% | Upgrade |
Operating Margin | 11.40% | 11.94% | 13.91% | 14.37% | 15.05% | 13.00% | Upgrade |
Profit Margin | 8.49% | 8.88% | 10.04% | 10.63% | 10.87% | 9.15% | Upgrade |
Free Cash Flow Margin | 9.93% | 13.93% | 8.41% | 2.55% | 3.35% | 7.24% | Upgrade |
EBITDA | 64.63 | 68.94 | 89.48 | 86.23 | 79 | 56.84 | Upgrade |
EBITDA Margin | 13.16% | 13.68% | 15.40% | 15.57% | 16.24% | 14.37% | Upgrade |
D&A For EBITDA | 8.63 | 8.77 | 8.64 | 6.64 | 5.8 | 5.43 | Upgrade |
EBIT | 56 | 60.17 | 80.84 | 79.59 | 73.2 | 51.41 | Upgrade |
EBIT Margin | 11.40% | 11.94% | 13.91% | 14.37% | 15.05% | 13.00% | Upgrade |
Effective Tax Rate | 26.03% | 26.10% | 26.88% | 25.49% | 27.52% | 29.08% | Upgrade |
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.